SCHEMBL6759554

SCHEMBL6759554

NN1OCCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928895 0.67
SCHEMBL1708922 0.67
SCHEMBL220469 0.67
SCHEMBL16612581 0.62
SCHEMBL12293895 0.62
SCHEMBL11261047 0.60
SCHEMBL48363 0.59
SCHEMBL2491333 0.57
SCHEMBL14536423 0.56
SCHEMBL2172251 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040214873-A1 Use of amino-isoxazolidone compounds for improvement of implicit memory G. D. SEARLE & CO. 2004-10-28 US disclosed
US-20040214873-A1 Use of amino-isoxazolidone compounds for improvement of implicit memory G. D. SEARLE & CO. 2004-10-28 US disclosed
US-20040214873-A1 Use of amino-isoxazolidone compounds for improvement of implicit memory G. D. SEARLE & CO. 2004-10-28 US disclosed
US-6656962-B2 Administering a therapeutically-effective amount of a glycine B partial agonist to improve implicit memory PHARMACIA CORPORATION 2003-12-02 US disclosed
US-6656962-B2 Administering a therapeutically-effective amount of a glycine B partial agonist to improve implicit memory PHARMACIA CORPORATION 2003-12-02 US disclosed
US-6656962-B2 Administering a therapeutically-effective amount of a glycine B partial agonist to improve implicit memory PHARMACIA CORPORATION 2003-12-02 US disclosed
US-20030073730-A1 Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury G.D. SEARLE & CO. (US) 2003-04-17 US disclosed
US-20030073730-A1 Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury G.D. SEARLE & CO. (US) 2003-04-17 US disclosed
US-20030073730-A1 Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury G.D. SEARLE & CO. (US) 2003-04-17 US disclosed
US-20020183373-A1 Use of amino-isoxazolidone compounds for improvement of lexical priming G.D. SEARLE & CO. 2002-12-05 US disclosed
WO-1996015788-A1 USE OF AMINO-ISOXAZOLIDONE COMPOUNDS FOR IMPROVEMENT OF IMPLICIT MEMORY G.D. SEARLE & CO. (US) 1996-05-30 WO disclosed
WO-1996015788-A1 USE OF AMINO-ISOXAZOLIDONE COMPOUNDS FOR IMPROVEMENT OF IMPLICIT MEMORY G.D. SEARLE & CO. (US) 1996-05-30 WO disclosed
WO-1996015787-A1 USE OF AMINO-ISOXAZOLIDONE COMPOUNDS FOR TREATMENT OF MEMORY IMPAIRMENT FOLLOWING TRAUMATIC BRAIN INJURY G.D. SEARLE & CO. (US) 1996-05-30 WO disclosed
WO-1996015787-A1 USE OF AMINO-ISOXAZOLIDONE COMPOUNDS FOR TREATMENT OF MEMORY IMPAIRMENT FOLLOWING TRAUMATIC BRAIN INJURY G.D. SEARLE & CO. (US) 1996-05-30 WO disclosed
US-5187171-A USE OF A GLYCINE B PARTIAL AGONIST AS AN ANTIPSYCHOTIC G. D. SEARLE & CO. (US) 1993-02-16 US disclosed
US-5187171-A USE OF A GLYCINE B PARTIAL AGONIST AS AN ANTIPSYCHOTIC G. D. SEARLE & CO. (US) 1993-02-16 US disclosed
EP-0378134-A3 USE OF A GLYCINE B PARTIAL AGONIST AS AN ANTIPSYCHOTIC G.D. Searle & Co. (US) 1991-07-17 EP disclosed
US-4999267-A ELECTROGRAPHY MINOLTA CAMERA KABUSHIKI KAISHA (JP) 1991-03-12 US disclosed
EP-0378134-A2 Use of a glycine B partial agonist as an antipsychotic G.D. Searle & Co. (US) 1990-07-18 EP disclosed
EP-0378134-A2 Use of a glycine B partial agonist as an antipsychotic G.D. Searle & Co. (US) 1990-07-18 EP disclosed